Dementia and its potential triggers have been a hot topic in neurology, with some surprising findings. The link between calcium supplements and dementia risk is a controversial one. A recent study reveals that taking calcium supplements for five years did not increase the chances of developing all-cause dementia over a 14.5-year period. But here’s where it gets interesting: this finding contradicts previous beliefs about calcium’s potential impact on cognitive health.
Moving on to vitamin B12, research from the Framingham Heart Study suggests that higher levels of this vitamin from midlife to late life are associated with slower cognitive decline. This is great news for those looking to maintain their cognitive health as they age.
And this is the part most people miss: blood platelet aggregation in midlife was linked to markers of Alzheimer’s disease pathology. This highlights the importance of understanding the early signs and potential risk factors for this debilitating disease.
In other news, a study on children diagnosed with autism or ADHD found that symptom severity corresponded to distinct patterns of brain connectivity and related gene expression. This research provides valuable insights into the unique neurological profiles of these conditions.
Now, let’s talk about multiple sclerosis (MS) and the promising results of the investigational Bruton’s tyrosine kinase inhibitor fenebrutinib. In a phase III study, fenebrutinib showed reduced annualized relapse rates compared to teriflunomide (Aubagio) in relapsing MS. Additionally, it was non-inferior to ocrelizumab (Ocrevus) in terms of disability progression in primary progressive MS.
However, not all trials yield positive results. The RECOVER-NEURO trial showed that none of the three evidence-based rehabilitation strategies improved cognitive symptoms in people with long COVID. This highlights the ongoing challenge of finding effective treatments for this complex condition.
In regulatory news, the FDA has rejected troriluzole for spinocerebellar ataxia. Biohaven, the developer of this drug, has expressed disappointment but remains committed to finding treatments for this rare condition.
On a more positive note, a patient-reported outcome tool combined with an electronic health record tool has shown promising results in increasing new dementia diagnoses by 31% in primary care clinics. This innovative approach could lead to earlier detection and better management of dementia.
Lastly, Texas voters have approved a measure to allocate $3 billion in state surplus funds for the new Dementia Prevention and Research Institute of Texas. This significant investment in dementia research and prevention is a step towards a brighter future for those at risk.
These recent developments in neurology and neuroscience showcase the ongoing efforts to understand and combat various neurological conditions. From controversial interpretations of calcium’s role in dementia to promising MS treatments, the field is constantly evolving. What are your thoughts on these findings? Do you think we’re getting closer to effective solutions for these complex health issues? Feel free to share your insights and opinions in the comments below!